Sort by
Refine Your Search
-
, Passionate about cellular metabolism, metabolic physiology, Familiarity with fibrosis biology, hepatic stellate cell activation Additional Information Eligibility criteria Mandatory: *PhD in Physiology
-
) Positions PhD Positions Application Deadline 4 May 2026 - 23:45 (Europe/Dublin) Country Ireland Type of Contract Temporary Job Status Full-time Hours Per Week 39 Is the job funded through the EU Research
-
researchers, either just after completion of a PhD or for someone entering a new area for the first time. If you have already completed your PD1 stage in UCD or will soon complete a PD1, or you are an external
-
position is intended for early stage researchers, either just after completion of a PhD or for someone entering a new area for the first time. If you have already completed your PD1 stage in UCD or will soon
-
position is intended for early stage researchers, either just after completion of a PhD or for someone entering a new area for the first time. If you have already completed your PD1 stage in UCD or will soon
-
partner with FutureNeuro, the Research Ireland Centre for Translational Brain Science. The Fitzgerald group in TCD will work closely with the Fitzgerald group in Queen’s University Belfast ( https
-
Agencies will be returned. The PD1 position is intended for early stage researchers, either just after completion of a PhD or for someone entering a new area for the first time. If you have already completed
-
. Any CV's submitted by Recruitment Agencies will be returned. The PD1 position is intended for early stage researchers, either just after completion of a PhD or for someone entering a new area for the
-
the selection process. For an information package including full details of the post, selection criteria and application process see https://ore.ucc.ie/. The University, at its discretion, may undertake to make
-
applications for a Clinical Research Fellow to work on the Acumen trial which is about to start recruitment at Cork University Maternity Hospital. The Acumen trial is a multi-centre phase I dose Escalation and